Companies › Orchid Pharma Europe
1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 4; Hematology, Infectious disease; next expected readout May 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Cefepime Bacterial penicillin-binding protein inhibitor | CEPE, ENME | Phase 2 | Complicated Urinary Tract Infection; Infection; Intestinal Microbiome | May 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03078010 | Cefepime | Phase 2 | Intestinal Microbiome | Hematology | Feb 2027 |
| NCT07484633 | Cefepime | Phase 4 | Infection | Infectious disease | Aug 2028 |
| NCT05826990 | Cefepime | Phase 2 | Complicated Urinary Tract Infection | Infectious disease | May 2029 |
S-INFINITY Pharmaceuticals Prothya Biosolutions Vasomune Therapeutics Altesa Biosciences Eagle Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.